Soluble Intercellular Adhesion Molecule 1 (ICAM-1) Antigen in Sera of Bronchial Asthmatics

Shiota, Yutaro; Wilson, James G.; Marukawa, Masaomi; Ono, Tetsuya; Kaji, Masahide

doi:10.1378/chest.109.1.94

Cited by 35 publications

(27 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this study, a soluble circulating form of the usually membrane–bound sICAM–1 was identified and measured in the sera of all healthy control children without a significant difference between boys and girls. The mean serum sICAM–1 level in normal children in our study was similar to that found by investigators [12, 14]in normal adults. No significant correlation between age and sICAM–1 levels could be detected in our study population either in healthy children or in asthmatic groups.…”

Section: Discussionsupporting

confidence: 92%

“…No such marker has yet been found for asthma. Although the reports on the level of serum sICAM–1 in healthy individuals and in inflammatory diseases (especially asthma) in adults are plethoric [14, 15, 20], those in children are scanty. In this study, a soluble circulating form of the usually membrane–bound sICAM–1 was identified and measured in the sera of all healthy control children without a significant difference between boys and girls.…”

Section: Discussionmentioning

confidence: 99%

“…Both asthmatic and control children were not taking any drugs which might affect ICAM–1 (e.g. corticosteroid [14]and antiallergic drugs [19]) for at least 2 weeks before enrollment into the study.…”

Section: Methodsmentioning

confidence: 99%

“…Based on the cell lines tested and the primary cell cultures, it appears that the sole source of cICAM–1 is from mononuclear cells [12]. The structural and functional characteristics of sICAM–1 suggest that it chould serve as a fluid–phase regulator of the adhesive interaction [12, 13, 14]. A soluble form of ICAM–1 (sICAM–1) was found in increased levels in patients with inflammatory, immune or malignant diseases [12, 14, 15, 16].…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Soluble Intercellular Adhesion Molecule–1 in Sera of Children with Bronchial Asthma Exacerbation

El-Sawy

Badr-El-Din²,

El-Azzouni³

et al. 1999

Int Arch Allergy Immunol

View full text Add to dashboard Cite

Previous studies have suggested that intercellular adhesion molecule–1 (ICAM–1; CD54) may be involved in the pathogenesis of asthma. In addition, a soluble form of intercellular adhesion molecule–1 (sICAM–1) has been detected in increased concentrations in the sera from adult patients with certain inflammatory, immune, or malignant diseases. To determine whether bronchial asthma exacerbation in children is associated with increased levels of serum sICAM–1 and to investigate the effect of the severity of exacerbation on these levels, the concentrations of sICAM–1 were measured in sera of 20 healthy control children and 45 asthmatic children (15 with mild, 15 with moderate, and 15 with severe asthma exacerbation) using an immunoenzymatic assay. Assessment of the severity of asthma exacerbation was based on clinical and physiological parameters. The mean (± SD) level of serum sICAM–1 for asthmatic children (390.0±108.3 ng/ml) was significantly higher than that for healthy (193.2±33.95 ng/ml; p = 0.000). We have also found a differential rise of serum sICAM–1 level which correlates well with the severity of asthma exacerbation. The elevated concentrations of serum sICAM–1 in acute bronchial asthma may reflect the extensive inflammatory response occurring in the airways during acute exacerbation of the disease with airway obstruction. The results of this study suggest that serum sICAM–1 is a promising serological marker of the severity of inflammation in bronchial asthma in children and it would not only facilitate staging of inflammation but also allow the monitoring of therapy and intervention.

show abstract

Section: Discussionsupporting

confidence: 92%

Section: Discussionmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Soluble Intercellular Adhesion Molecule–1 in Sera of Children with Bronchial Asthma Exacerbation

El-Sawy

Badr-El-Din²,

El-Azzouni³

et al. 1999

Int Arch Allergy Immunol

View full text Add to dashboard Cite

show abstract

“…The levels of ICAM-1 in serum from asthmatics were higher than in healthy subjects and likewise, the levels of VCAM-1 in serum obtained during asthmatic episodes were higher than those obtained in stable condition [43,44]. VCAM-1 and ICAM-1 levels in BAL fluid were also shown to be elevated after allergen challenge [45,46].…”

Section: Discussionmentioning

confidence: 81%

Soluble vascular cell adhesion molecule (VCAM)-Fc fusion protein induces leukotriene C4 secretion in platelet-activating factor-stimulated eosinophils

Tsuruta

Cobb

Mastrangelo

et al. 1999

Journal of Leukocyte Biology

View full text Add to dashboard Cite

International consensus statement on allergy and rhinology: Allergic rhinitis – 2023

Wise

Damask

Roland

et al. 2023

Int Forum Allergy Rhinol

113

View full text Add to dashboard Cite

Background In the 5 years that have passed since the publication of the 2018 International Consensus Statement on Allergy and Rhinology: Allergic Rhinitis (ICAR‐Allergic Rhinitis 2018), the literature has expanded substantially. The ICAR‐Allergic Rhinitis 2023 update presents 144 individual topics on allergic rhinitis (AR), expanded by over 40 topics from the 2018 document. Originally presented topics from 2018 have also been reviewed and updated. The executive summary highlights key evidence‐based findings and recommendation from the full document. Methods ICAR‐Allergic Rhinitis 2023 employed established evidence‐based review with recommendation (EBRR) methodology to individually evaluate each topic. Stepwise iterative peer review and consensus was performed for each topic. The final document was then collated and includes the results of this work. Results ICAR‐Allergic Rhinitis 2023 includes 10 major content areas and 144 individual topics related to AR. For a substantial proportion of topics included, an aggregate grade of evidence is presented, which is determined by collating the levels of evidence for each available study identified in the literature. For topics in which a diagnostic or therapeutic intervention is considered, a recommendation summary is presented, which considers the aggregate grade of evidence, benefit, harm, and cost. Conclusion The ICAR‐Allergic Rhinitis 2023 update provides a comprehensive evaluation of AR and the currently available evidence. It is this evidence that contributes to our current knowledge base and recommendations for patient evaluation and treatment.

show abstract

Soluble Intercellular Adhesion Molecule 1 (ICAM-1) Antigen in Sera of Bronchial Asthmatics

Cited by 35 publications

References 17 publications

Soluble Intercellular Adhesion Molecule–1 in Sera of Children with Bronchial Asthma Exacerbation

Soluble Intercellular Adhesion Molecule–1 in Sera of Children with Bronchial Asthma Exacerbation

Soluble vascular cell adhesion molecule (VCAM)-Fc fusion protein induces leukotriene C4 secretion in platelet-activating factor-stimulated eosinophils

International consensus statement on allergy and rhinology: Allergic rhinitis – 2023

Contact Info

Product

Resources

About